Clinical outcomes after CAVEAT therapy. (A) Clinical response (best response at any time on study) for all patients and by key molecular subgroups (most frequently occurring gene mutations). (B) OS of all patients. (C) OS stratified by de novo vs secondary AML. (D) OS stratified by ELN 2022 risk classification5: pairwise comparisons between the 3 risk groups show significant differences only between favorable and adverse risk (P = .02; ∗, corrected for multiple testing), with nonsignificant P values for favorable vs intermediate (P = .218) and intermediate vs adverse (P = 1.00). (E-H) OS stratified by mutation status: (E) IDH1/2 mut vs wt, (F) NPM1 mut vs wt, (G) TP53 mut vs wt, and (H) SRSF2 mut vs wt. CI, confidence interval; CRh, CR with partial hematologic recovery; CRi, CR with incomplete count recovery; mut, mutant; MLFS, morphologic leukemia free state; NA, not assessable; wt, wild-type.
